{
    "relation": [
        [
            "",
            "ATV 300 mg / RTV",
            "ATV 400 mg / SQV",
            "LPV / RTV"
        ],
        [
            "Description",
            "ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study",
            "ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study",
            "LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
        ]
    ],
    "pageTitle": "Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00035932?sect=X01256&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 125,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989142.82/warc/CC-MAIN-20150728002309-00200-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868806607,
    "recordOffset": 868772612,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{4346=ATV 400 mg + saquinavir (SQV) 1200 mg + TDF 300 mg + nucleoside of choice, 17671=ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice}",
    "textBeforeTable": "Reporting Groups 571 human immunodeficiency virus (HIV)-infected participants were enrolled; 358 (63%) were randomized to treatment. Of the 213 not randomized, 194 did not meet eligibility criteria; other reasons include duplicate enrollment (4), accrual closed (1), noncompliance (1), serious adverse event (2), patient request (11), missing information (4). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Atazanavir + ritonavir + tenofovir + nucleoside Drug: Atazanavir + saquinavir + tenofovir + nucleoside Drug: Lopinavir/ritonavir + tenofovir + nucleoside Interventions: HIV Infections Condition:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 ATV 300 mg / RTV \u00a0 \u00a0 ATV 400 mg / SQV \u00a0 \u00a0 LPV / RTV \u00a0 STARTED \u00a0 \u00a0 119 [1] \u00a0 110 [2] \u00a0 118 [3] Discontinued Prior to Week 48 Visit \u00a0 \u00a0 26 \u00a0 \u00a0 29 \u00a0 \u00a0 13 \u00a0 Discontinued Between Weeks 48 and 96 \u00a0 \u00a0 26 \u00a0 \u00a0 27 \u00a0 \u00a0 30 \u00a0 Discontinued on or After Week 96 \u00a0 \u00a0 4 \u00a0 \u00a0 4 \u00a0 \u00a0 6 \u00a0 COMPLETED \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}